What's the Difference Between a Stem Cell and a Progenitor Cell?

What This Article Covers

"Stem cell" gets used as a catch-all term, but not every cell in a "stem cell treatment" is actually a stem cell in the strict biological sense. Many are progenitor cells — closely related, still useful, but meaningfully different in what they can do and for how long. Understanding this one distinction is one of the most practical things a newcomer can learn, because it changes how you read a clinic's marketing, a product insert, or a headline promising a "stem cell cure."

The Core Definition: Self-Renewal Is the Dividing Line

Biologists define a true stem cell by two properties working together: it can make more of itself indefinitely (self-renewal), and it can also produce specialized, differentiated cells. The National Institutes of Health's Stem Cell Basics resource describes this as the "remarkable potential" of stem cells to renew themselves and to develop into many different cell types in the body. When a stem cell divides, it can produce two new stem cells, one stem cell and one differentiated cell, or two differentiated cells — and what tips that balance one way or another isn't yet fully understood, according to NIH.

A progenitor cell, by contrast, is a step further down the developmental ladder. It's already more specialized than a stem cell, it's typically committed to producing one particular lineage of cell (say, red blood cells, or a certain type of skin cell), and — critically — it can only divide a limited number of times before it runs out of replicative capacity. Think of a stem cell as a renewable resource and a progenitor cell as a large but finite supply: both are useful, but they behave very differently over time.

Why This Distinction Isn't Just Semantics

This might sound like a fine academic point, but it has real consequences. A population of true stem cells can, in principle, keep replenishing a tissue for a very long time. A population of progenitor cells does real, valuable work — but it eventually exhausts itself and needs to be replaced by upstream stem cells that are dividing more slowly and more rarely, precisely to conserve their long-term capacity. This is why, in tissues like bone marrow, the actual stem cells are rare and largely quiet, while the more numerous, faster-dividing progenitor cells are the ones churning out mature blood cells day to day.

A Concrete Example: Blood Formation

Hematopoietic (blood-forming) tissue is the best-studied illustration of this hierarchy. At the top sit hematopoietic stem cells — rare, capable of self-renewal, and able to give rise to every kind of blood and immune cell over a person's lifetime. Below them sit a series of hematopoietic progenitor cells, which have already narrowed their fate toward a particular blood cell family and divide rapidly to produce large numbers of mature cells, but without the same long-term self-renewing capacity as the stem cells above them. Both cell types matter clinically — cord blood transplants, for instance, work partly because they contain a mix of stem and progenitor cells — but they are not interchangeable, and researchers characterize them separately using specific cell-surface markers.

What This Means for "Stem Cell" Products You'll Encounter

Here's where the distinction becomes genuinely practical. Many products marketed as "stem cell therapy" — particularly those derived from a patient's own fat tissue (often called stromal vascular fraction) or bone marrow — are not purified populations of true stem cells. They're heterogeneous mixtures that can include a minority of stem and progenitor cells alongside various other cell types, secretory cells, and connective tissue components, in proportions that vary from person to person and even from one collection to the next. That doesn't necessarily make these products worthless — but it does mean the label "stem cell injection" can overstate what's actually inside the syringe.

This issue extends even to how certain cells are named. Mesenchymal "stem" cells (MSCs) — widely used in orthopedic and joint-injection products — are a case in point. In an influential 2017 paper, stem cell researcher Arnold Caplan, who helped popularize the MSC term decades earlier, argued the name itself is misleading: these cells rarely differentiate into new tissue once injected into the body. Their real, better-documented effect is that they secrete signaling molecules that calm inflammation and nudge the body's own resident repair cells into action — a mechanism, not a replacement. Caplan proposed the field instead call them "Medicinal Signaling Cells." Whether or not that renaming catches on, the underlying point stands: a cell being labeled a "stem cell" doesn't tell you whether it behaves like one.

How This Shapes Marketing Claims — and How to Read Them

This gap between label and biology is exactly where consumer-facing overreach tends to creep in. Reporting on the regenerative medicine industry has repeatedly found that products marketed as "stem cell" injections often don't contain a meaningful concentration of true, self-renewing stem cells at all — and that clinics have promoted these products for uses, like reversing arthritis or regrowing cartilage, that current evidence doesn't support. The FDA has issued consumer alerts specifically warning patients that many regenerative products sold outside of approved clinical trials or regulatory pathways haven't been proven safe or effective for the conditions they're marketed for.

None of this means progenitor cells are a lesser or fraudulent ingredient — far from it. Progenitor and precursor cells are the working basis of some of medicine's most established cell therapies, including decades of successful bone marrow and cord blood transplantation. The problem isn't the biology; it's when marketing borrows the prestige of "stem cell" language for products that are, at best, only partly stem cells — or don't even attempt to specify what fraction of the injected material actually qualifies. A good general rule: any reputable source describing a cell product should be able to tell you, at least approximately, what's actually in it.

Bottom Line

Stem cells and progenitor cells are related but distinct: stem cells can renew themselves indefinitely and generate multiple cell types, while progenitor cells are more specialized, more limited in how many times they can divide, and usually committed to a single lineage. Both play legitimate, important roles in the body and in established medicine — but the blurring of these terms in commercial marketing is a genuine problem. When evaluating any "stem cell" product or claim, it's reasonable to ask what cell types are actually present, in what proportion, and what evidence supports the specific claim being made — questions the underlying biology makes possible to ask in the first place.